Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PF-07940369 in Healthy Adults
NCT06532383Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07940369 in anemia of clonal hematopoiesis (2 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events, Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities and 3 more. Started Aug 2024; status: completed.
02
Drugs
PF-07940369
03
Conditions
anemia of clonal hematopoiesis
Beyond the preview
Go deeper on NCT06532383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532383.